CervoMed publishes Phase 2b DLB trial paper; primary outcome not confirmed
On October 29, 2026, CervoMed announced two peer-reviewed publications on neflamapimod for dementia with Lewy bodies (DLB). The placebo-controlled RewinD-LB Phase 2b trial, published in Alzheimer's Research & Therapy, did not confirm the Phase 2a results on its primary outcome in the full patient population, though the company cites subgroup and biomarker findings it says support further development.
Key points
- RewinD-LB trial (159 patients) did not confirm the Phase 2a AscenD-LB primary outcome, change in CDR-SB, in the full intention-to-treat population.
- In patients without Alzheimer's co-pathology (pTau181 <23 pg/mL), the placebo-adjusted CDR-SB difference was −0.51 points (95% CI: −1.16 to 0.13).
- Discontinuation due to adverse events was 2.5% with neflamapimod and 1.3% with placebo.
- The company is focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.